Search by Drug Name or NDC
NDC 24979-0703-06 Dexlansoprazole 30 mg/1 Details
Dexlansoprazole 30 mg/1
Dexlansoprazole is a ORAL CAPSULE, DELAYED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by TWI PHARMACEUTICALS, INC.. The primary component is DEXLANSOPRAZOLE.
MedlinePlus Drug Summary
Dexlansoprazole is used to treat the symptoms of gastroesophageal reflux disease (GERD; a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus [tube between the throat and stomach]) in adults and children 12 years of age and older. It is also used to treat esophagitis (swelling that may damage tissues of the esophagus) in adults and children 12 years of age and older. Dexlansoprazole is used for the maintenance treatment of esophagitis and healing in adults and children 12 years of age and older. Dexlansoprazole is in a class of medications called proton pump inhibitors. It works by decreasing the amount of acid made in the stomach.
Related Packages: 24979-0703-06Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Dexlansoprazole
Product Information
| NDC | 24979-0703 |
|---|---|
| Product ID | 24979-703_cceebcc4-476b-4e95-a711-9a58936a16bf |
| Associated GPIs | 49270020006520 |
| GCN Sequence Number | 064793 |
| GCN Sequence Number Description | dexlansoprazole CAP DR BP 30 MG ORAL |
| HIC3 | D4J |
| HIC3 Description | PROTON-PUMP INHIBITORS |
| GCN | 16305 |
| HICL Sequence Number | 036085 |
| HICL Sequence Number Description | DEXLANSOPRAZOLE |
| Brand/Generic | Generic |
| Proprietary Name | Dexlansoprazole |
| Proprietary Name Suffix | delayed release |
| Non-Proprietary Name | dexlansoprazole |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE, DELAYED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 30 |
| Active Ingredient Units | mg/1 |
| Substance Name | DEXLANSOPRAZOLE |
| Labeler Name | TWI PHARMACEUTICALS, INC. |
| Pharmaceutical Class | Proton Pump Inhibitor [EPC], Proton Pump Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA AUTHORIZED GENERIC |
| Application Number | NDA022287 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 24979-0703-06 (24979070306)
| NDC Package Code | 24979-703-06 |
|---|---|
| Billing NDC | 24979070306 |
| Package | 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (24979-703-06) |
| Marketing Start Date | 2022-01-01 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 6.89929 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | DEXLANSOPRAZOLE DR 30 MG CAP |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1, 6 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |